

Guideline

Non-Cystic Fibrosis Bronchiectasis - Antimicrobial Therapy for Children

Document ID	CHQ-GDL-01072	Version no.	4.0	Approval date	25/08/2023
Executive sponsor	Executive Director of Medical Services			Effective date	31/08/2023
Author/custodian	Director of Respiratory Medicine Director of Infection Management and Prevention service, Immunology and Rheumatology			Review date	25/08/2025
Supersedes	3.0				
Applicable to	All Children's Health Queensland Staff				
Authorisation	Executive Director Clinical Services				

Purpose

This guideline provides Children's Health Queensland (CHQ) recommendations regarding best practice for empirical antimicrobial therapy for paediatric patients with non-cystic fibrosis (non-CF) bronchiectasis including inpatient and outpatient management.

Scope

This guideline provides information for CHQ staff involved in the care of paediatric respiratory patients with non-CF bronchiectasis.

Related documents

- [CHQ Paediatric medication guidelines: IV Aminoglycosides](#)
- [CHQ@Home Outpatient Parenteral Antimicrobial Therapy Prescribing, Administration and monitoring guideline](#)
- [CHQ-PROC-01036 Antimicrobial: Prescribing and Management](#)
- [CHQ Antimicrobial Restriction list](#)
- [CHQ-GDL-01221 Immunisation Guideline for Medically at Risk Children](#)

Guideline

Empirical Antimicrobial Therapy for Children with Non-Cystic Fibrosis Bronchiectasis

Part 1. Summary table of empirical antimicrobial therapy for children with Non-CF bronchiectasis

- Acute Exacerbation (empirical)
- Recurrent Exacerbation (empirical)
- Acute Exacerbation with Methicillin Sensitive Staphylococcus Aureus (MSSA)
- Acute Exacerbation with Methicillin Resistant Staphylococcus Aureus (MRSA)
- Pseudomonas aeruginosa
 - First/new isolation without exacerbation
 - First/new isolation with exacerbation
 - Chronic Pseudomonas aeruginosa (PsA) with exacerbation

Part 2. Summary table of antibiotic doses recommended in patients with Non CF bronchiectasis

- Additional monitoring whilst on intravenous (IV) antibiotics
- Intravenous antibiotics
- Oral antibiotics
- Inhaled or nebulised antibiotics

Part 3. Hospital In The Home (HITH)

Part 4. Use of Azithromycin in Children with Non-Cystic Fibrosis Bronchiectasis or Chronic Suppurative Lung Disease

Part 1. Table 1: Summary table of empirical antimicrobial therapy for infants over 1 month of age; children and adolescents with non-CF bronchiectasis

For neonates or patients with renal/liver disease, seek specialist advice. For patients with a history of immediate or delayed type penicillin and/or cephalosporin hypersensitivity, please consult the Infectious Diseases team (ID) for advice on treatment options prior to commencement of antibiotics.

Clinical Scenario	Setting	Antibiotic (Dosing recommendations – see Part 2)	Duration	Alternative antibiotic	Comments
Acute Exacerbation (empirical)	Inpatient OR HITH*	IV Cefotaxime OR IV Ceftriaxone*	10 to 14 days	IV Amoxicillin-clavulanate	IV Amoxicillin-clavulanate is not suitable for HITH
	Outpatient	Oral Amoxicillin-clavulanate	2 to 4 weeks	(1) Oral Trimethoprim/sulfamethoxazole (note: limited activity against <i>Haemophilus influenzae</i>) (2) Oral Azithromycin (daily dosing) if non severe or severe penicillin hypersensitivity	If improving, adjustment of antibiotic therapy based on the results of sputum culture is not required. If not improving, check microbiology for directed antibiotic therapy.
Recurrent Exacerbation (empirical)	Outpatient	Oral Azithromycin (as anti-inflammatory) [10 mg/kg three times a week, on Mondays, Wednesdays and Fridays; maximum 500 mg/dose]			Exclude non-tuberculous mycobacteria infection. See Part 4 below
Acute Exacerbation with Methicillin Resistant <i>Staphylococcus Aureus</i> (MRSA)	Inpatient or Outpatient	Tailor to susceptibility			Discuss with Paediatric Infection Specialist

Table 1: Summary table of empirical antimicrobial therapy for infants over 1 month of age; children and adolescents with non-CF bronchiectasis (continued)

Clinical Scenario	Setting	Antibiotic (Dosing recommendations – see Part 2)	Duration	Alternative antibiotic	Comments
First/new isolation of <i>Pseudomonas aeruginosa</i> (PsA) without exacerbation	Outpatient	(1) Oral Ciprofloxacin OR Inhaled tobramycin (preservative free) OR both <i>Followed by</i> (2) Inhaled tobramycin (preservative free)	14 days 4 to 12 weeks		Treat <i>Pseudomonas</i> isolated on lower airway specimen only (lavage or sputum). 2 nd attempt at clearance: Use or repeat dual therapy.
First/new isolation of <i>Pseudomonas aeruginosa</i> (PsA) with exacerbation	Inpatient OR HITH*	IV Piperacillin/Tazobactam* OR IV Ceftazidime* <i>With or without either</i> IV Tobramycin OR Inhaled tobramycin (preservative free) <i>Followed by</i> Inhaled Tobramycin (preservative free)	14 days 14 days 4 to 12 weeks	If PsA resistant to Tobramycin and failure of first line eradication regimen, can consider 12 weeks nebulised colistin. ID approval required.	Dual anti-pseudomonal antibiotic therapy is controversial. Consider the harms and benefits of combination therapy and check for contraindications and precautions before prescribing aminoglycosides.
	Outpatient	(1) Oral Ciprofloxacin OR Inhaled tobramycin (preservative free) OR both <i>Followed by</i> (2) Inhaled tobramycin (preservative free)	14 days 4 to 12 weeks	.	2 nd attempt at clearance: use or repeat dual therapy.

Table 1: Summary table of empirical antimicrobial therapy for infants over 1 month of age; children and adolescents with non-CF bronchiectasis (continued)

Clinical Scenario	Setting	Antibiotic (Dosing recommendations – see Part 2)	Duration	Alternative antibiotic	Comments
Chronic <i>Pseudomonas aeruginosa</i> (PsA) with exacerbation	Outpatient	Inhaled tobramycin (preservative free) <i>With or without</i> Oral Ciprofloxacin	2 to 4 weeks		Treat <i>Pseudomonas</i> isolated on lower airway specimen only (lavage or sputum). Where lower airway specimens unable to be obtained (eg Cerebral palsy / neuromuscular disorders) <i>pseudomonas</i> often reflects upper airway colonisation and first line exacerbation therapy should be:
	Inpatient	IV Piperacillin/Tazobactam* OR IV Ceftazidime* <i>With or without either</i> IV Tobramycin OR Inhaled tobramycin (preservative free)	14 days	Use IV tobramycin instead of inhaled tobramycin if already used previously and no or limited response to inhaled therapy	Oral Amoxicillin/clavulanic acid OR IV Ceftriaxone as per Acute Exacerbation (empirical) above .

Part 2. Table 3: Summary table antibiotic doses recommended for paediatric patients with non CF bronchiectasis with normal renal function (including oral, IV and inhaled antibiotics)

Some IV medications require therapeutic drug monitoring (TDM). See table for recommendations. Consider impact of patient/disease factors that may impact on TDM results, for example:

- Liver disease (risk of hepato-renal syndrome).
- Concomitant nephrotoxic medications (e.g. Tacrolimus, NSAIDs).
- Hydration status (consider oral fluid intake, fasting status, input/output including diarrhoea/vomiting).
- Age (impact of hormonal changes on body composition and organ function during adolescence).

Antimicrobial	Recommended starting doses for infants, children and adolescents with non CF bronchiectasis (For neonates or patients with renal/liver disease, seek specialist advice)	ID approval required for patients with non CF bronchiectasis
Amoxicillin-clavulanate	Oral: 25 mg/kg/dose twice daily (maximum 875 mg/dose amoxicillin component)	No
	Intravenous: 25 mg/kg/dose IV 6-hourly (maximum 1 g/dose amoxicillin component)	Yes
Azithromycin	Oral: (treatment): 10 mg/kg once daily (Maximum 500 mg/day) for 5 days Note: Azithromycin has a very long half-life (54.5 hours in children)	Yes
	Oral: (anti-inflammatory for chronic lung disease) Patient less than 25 kg weight : 30 mg/kg per week (may be given in divided doses on a daily basis, three times weekly or as a single weekly dose) Patient 25 to 40 kg weight: 250 mg/dose three times weekly Patient >40kg weight: 500 mg/dose three times weekly	No. See Part 4 for eligibility criteria.
Cefotaxime	Intravenous: 50 mg/kg/dose 6-hourly (maximum 2 g/dose)	No (up to 14 days)
Ceftazidime	Intravenous: 50 mg/kg/dose 8-hourly (maximum 2 g/dose)	No (inpatient – if used according to guideline criteria) Yes (HITH)
Ceftriaxone	Intravenous: 100mg/kg once daily (maximum 4 g/day)	No (up to 14 days)
Cefuroxime	Oral: 15 mg/kg (maximum 500 mg) twice daily	No
Ciprofloxacin	Oral: 10 to 15 mg/kg/dose twice daily (12 hourly) (maximum 750 mg /dose) Oral ciprofloxacin has poor palatability, consider rounding doses to the nearest 125 mg (if appropriate based on weight) to reduce need to manipulate the dose form. For children unable to swallow tablets whole, discuss options to improve adherence with the Pharmacist. Monitor compliance closely.	No (if used according to guideline criteria)
Colistin	Nebulised: 1 to 2 years of age: 1 million units inhaled 12 hourly 2 to 18 years of age: 1 to 2 million units inhaled 12 hourly (for eradication: 2 million units inhaled 12 hourly) The dose administered of Colistin depends mostly on the concentration of the drug used and the tidal volume of the patient however the nebuliser characteristics are also very important and maintenance of the nebuliser is also critical (29). Seek Respiratory consultant advice on nebulised dosing.	Yes

Table 3: Summary table antibiotic doses recommended for paediatric patients with non CF bronchiectasis with normal renal function (including oral, IV and inhaled antibiotics) (continued)

Antimicrobial	Recommended starting doses for infants, children and adolescents with non CF bronchiectasis (For neonates or patients with renal/liver disease, seek specialist advice)	ID approval required for patients with non CF bronchiectasis
Flucloxacillin	Intravenous: 50 mg/kg/dose 6-hourly (maximum 2 g/dose)	No
	Oral: 25 mg/kg/dose four times a day (6-hourly) (maximum 1 g/dose)	No
Piperacillin/ Tazobactam	Intravenous: More than 1 month of age: 100 mg/kg/dose 6-hourly (maximum 4 g/dose piperacillin component)	No (inpatient – if used according to guideline criteria) Yes (HITH)
Tobramycin	Intravenous: Dose based on adjusted body weight. <ul style="list-style-type: none"> For dosing and monitoring guidance, please refer to the CHQ Paediatric medication guidelines: IV Aminoglycosides 	No (inpatient – if used according to guideline criteria) Yes (HITH)
	Inhaled: Option 1: All ages – Tobramycin 300mg inhaled twice daily <ul style="list-style-type: none"> Use Tobramycin 300mg/5mL preservative free ampoules for inhalation Patients treated at Queensland Children's hospital (QCH): No ID approval or Individual patient approval (IPA) required if managed according to criteria detailed in this guideline. Outside this criteria, ID approval required. Patients receiving treatment at another Queensland Health hospital: Individual patient approval (IPA) required to facilitate supplies (non LAM indication for this formulation). ID approval as per local practices. Option 2: All ages - Tobramycin 160 mg inhaled twice daily <ul style="list-style-type: none"> Use Tobramycin 80mg/2mL preservative free ampoules Meets LAM criteria – No IPA required. 	No (QCH – if used according to guideline criteria) Other sites: ID approval as per local practices
Trimethoprim/ Sulfametho- xazole	Oral: 4 mg/kg/dose 12-hourly (maximum 160 mg/dose Trimethoprim component). For MRSA eradication, please consult ID team for advice on dose.	No

Part 3: Hospital In The Home (HITH)

- Contact the CHQatHome pharmacist/ AMS pharmacist for advice on drug stability and suitable administration device/method. For more information, please refer to [Table 1 - Suitability of parenteral antimicrobials for HITH use in paediatrics](#) on the HITH section of the CHQ Antimicrobial Stewardship Website.
- For more information on paediatric dosing, administration and monitoring of HITH antimicrobial therapy, refer to: [CHQ@Home Outpatient Parenteral Antimicrobial Therapy Prescribing, Administration and monitoring guideline](#) (available via [CHQ AMS Website](#)).
- **The following pre-approved HITH antimicrobial options are available for patients with non-CF bronchiectasis:**
 - IV ceftriaxone (one daily) for up to 14 day course. ID approval is required for more than 14 days of treatment.
- **The following HITH antimicrobial options for patients with non-CF bronchiectasis require ID approval:**
 - For Pseudomonas eradication:
 - IV Piperacillin/Tazobactam (as continuous infusion via ambulatory device) +/- IV Tobramycin (once daily – infused over 30 minutes) for up to 14 day course.
 - OR
 - IV Ceftazidime (as 8-hourly dosing – each dose administered over 30 minutes via Intermate® ambulatory device) +/- IV Tobramycin (once daily infused over 30 minutes) for up to 14 day course.
 - Ceftazidime doses administered by parent/carer after successful completion of CHQ competency training package “Guide to giving your child’s IV antibiotic at home – for children with PICC lines”) for up to 14 day course.
- All other home parenteral antimicrobial therapy requires ID approval prior to making (HITH) referral. Written confirmation of ID approval needs to accompany CHQ@Home (HITH) referral form and/or electronic medical record (ieMR).

Part 4: Use of Azithromycin in Children with Non-Cystic Fibrosis Bronchiectasis or Chronic Suppurative Lung Disease

Background

Appropriate use of antibiotics is one of the key treatment principles. Use of maintenance antibiotics should be restricted to selected children with bronchiectasis and when doing so, the child should be closely monitored with consideration to cease these antibiotics after a period of 6 to 24 months.

Azithromycin is a macrolide antibiotic with anti-inflammatory and immuno-modulatory properties. Based on current evidence, a trial of azithromycin therapy for 6 to 24 months to reduce respiratory exacerbations in carefully selected children with non-CF bronchiectasis can be justified under the circumstances presented below [9,10,16].

Prior to initiation of azithromycin as maintenance therapy, the following are required:

- Presence of bronchiectasis or CSLD
- Child has had ≥ 3 exacerbations and/or ≥ 2 hospitalisations in previous 12 months
- Child has been reviewed by a respiratory consultant
- Previous documented absence of non-tuberculous mycobacteria in the lower airways. If child can produce sputum, culture the sputum for acid fast bacilli.
- Child is regularly followed up with other standard therapies for non-CF bronchiectasis optimised
- Consider doing liver function test and ECG if other risk factors are present.

Exclusion criteria

- Patients with microbiological evidence of non-tuberculous mycobacterial infection
- Allergy to macrolides
- Abnormal liver function tests
- Clinically significant drug interaction with existing therapy (eg QT prolongation in patients receiving anti-arrhythmics).

At follow-up (minimum at 6 months post initiation)

- Review effect of azithromycin on frequency of exacerbations and other clinical aspects
- Consider repeating liver function test
- Repeat sputum (if sputum can be obtained)

Azithromycin prophylaxis dosing schedule

- Patient less than 25 kg weight: 30 mg/kg per week (may be given in divided doses on a daily basis, three times weekly or as a single weekly dose)
- Patient 25 to 40 kg weight: 250 mg/dose three times weekly
- Patient >40kg weight: 500 mg/dose three times weekly

Assessing benefit

- Patients requiring azithromycin for more than 6 months will require 6 monthly review and assessment of ongoing benefit and safety monitoring.
- Formal review by a Paediatric Respiratory Consultant at 12 months to assess benefit:
 - Reduction in frequency and/or severity of exacerbations, wet cough or sputum
 - Improvement in respiratory function
 - Improvement in general well-being (eg weight gain, school loss, behaviour)
 - Patient or family demonstrated capacity for regular review while on long term therapy
 - Surveillance of macrolide resistance patterns on microbiology results (if sputum can be obtained)

Ceasing azithromycin after 6 to 24 months (or earlier)

- Not tolerating the medication
- No clinical benefit demonstrated after a 6 month trial of the antibiotic
- Anticipated spontaneous clinical improvement based upon prior history (e.g. over summer)
- Discontinue azithromycin for a trial 3 to 6 month period after 24 months of continuous use, since there is limited long-term safety and efficacy data and the condition frequently shows improvement over time.
- If after a trial of cessation (2 months or more off azithromycin), the child fulfils the criteria of deterioration (≥ 3 exacerbations and/or ≥ 2 hospitalisations in previous 12 months, pro-rata), azithromycin may be recommenced with formal review by a Paediatric Respiratory Consultant to assess benefit at 6 months and every 6 months for a further 12 months.
- Every 12 months, a 2 month or longer trial of azithromycin cessation should be tried to assess continued clinical requirement. Azithromycin may be continued in this way with Paediatric Respiratory Consultant review.

ALERT

Azithromycin increases the risk of diarrhea and abdominal pain



Azithromycin increases population-level macrolide resistance rates for several types of respiratory bacteria, including *S pneumoniae* (both invasive and clinical isolates) and *S pyogenes* also has a strong selection pressure for other multidrug resistant (MDR) pathogens, including increased risk of penicillin resistance [11, 12] or community acquired MRSA [13].

Consultation

Key stakeholders who reviewed this version:

- Paediatric Respiratory Consultant and Fellow Team (CHQ)
- Paediatric Infectious Diseases Consultant and Fellow team (IMPS, CHQ)
- Pharmacist Advanced - Antimicrobial Stewardship (CHQ)
- CHQ Medical Advisory Committee endorsed 17/08/2023

List of abbreviations

Abbreviation	Definition
AMS	Antimicrobial Stewardship
CHQ	Children's Health Queensland
CKN	Clinician's Knowledge Network
HITH	Hospital in the Home
IMPS	Infection Prevention and Management Service
ID	Infectious Diseases Team
IV	Intravenous
LAM	Queensland Health List of Approved Medicines
MRSA	Methicillin Resistant Staphylococcus Aureus
MSSA	Methicillin Sensitive Staphylococcus Aureus
Non CF	Non cystic fibrosis
PBS	Pharmaceutical Benefit Scheme
PO	Per oral
PsA	Pseudomonas aeruginosa
QCH	Queensland Children's Hospital
SAS	Special Access Scheme
TDM	Therapeutic Drug Monitoring
WHO	World Health Organization

References and suggested reading

1. Chang AB, Bush A, Grimwood K. Bronchiectasis in children: diagnosis and treatment. *Lancet* 2018; 392: 866-79.
2. Chang AB, Bell SC, Byrnes CA, Dawkins P, Holland AE, Kennedy E, King PT, Laird P, Mooney S, Morgan L, Parsons M, Poot B, Toombs M, Torzillo PJ, Grimwood K. [Thoracic Society of Australia and New Zealand \(TSANZ\) position statement on chronic suppurative lung disease and bronchiectasis in children, adolescents and adults in Australia and New Zealand.](#) *Respirology*. 2023;28(4):339-349.
3. Langton Hewer SC, Smyth AR. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. *Cochrane Database Syst Rev* 2017; 4: CD004197.
4. Polverino E, Goeminne PC, McDonnell JM, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. *Eur Respir J* 2017; 50: 1700629 [https://doi.org/10.1183/13993003.00629-2017].
5. Murray MP, Turnbull K, Macquarrie S, Hill AT. Assessing response to treatment of exacerbations of bronchiectasis in adults. *Eur Respir J* 2009; 33: 312-318.
6. Kapur N, Masters IB, Chang AB. Longitudinal growth and lung function in pediatric non-CF bronchiectasis - what influences lung function stability? *Chest* 2010; 138: 158-164.
7. Chang AB. Pediatric Cough: Children Are Not Miniature Adults. *Lung* 2010; 188: S33-40.
8. Goyal V, Grimwood K, Chang AB. Bronchiectasis: the arrival of better evidence. *Lancet Respir Med* 2014; 2: 12-13.

9. Chang AB, Bell SC, Byrnes CA, Grimwood K, Holmes PW, King PT, Kolbe J, Landau LI, Maguire GP, McDonald MI, Reid DW, Thien FC, Torzillo PJ. Bronchiectasis and chronic suppurative lung disease (CSLD) in children and adults in Australian and New Zealand: Thoracic Society of Australia and New Zealand and Australian Lung Foundation Position Statement. *Med J Aust* 2010; 193: 356-365.
10. Valery PC, Morris PS, Byrnes CA, Grimwood K, Torzillo PJ, Bauert P, Masters IB, Diaz A, McCallum GB, Mobberly C, Tjhung I, Hare KM, Ware RS, Chang AB. Long term azithromycin for Indigenous children with non-cystic fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multi-centre, double-blind randomised controlled trial. *Lancet Respir Med* 2013; 1: 610-620.
11. Serisier DJ. Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases. *Lancet Respir Med*. 2013 May;1(3):262-74. doi: 10.1016/S2213-2600(13)70038-9. Epub 2013 Mar 29.
12. Garcia-Rey C, Aguilar L, Baquero F, Casal J, Dal-Ré R. Importance of local variations in antibiotic consumption and geographical differences of erythromycin and penicillin resistance in *Streptococcus pneumoniae*. *J Clin Microbiol* 2002; 40: 159–64
13. Schneider-Lindner V, Delaney JA, Dial S, Dascal A, Suissa S. Antimicrobial drugs and community-acquired methicillin resistant *Staphylococcus aureus*, United Kingdom. *Emerg Infect Dis* 2007; 13: 994–1000.
14. Chang AB, Fortescue R, **Grimwood K**, Alexopoulou E, Bell L, Boyd J, Bush A, Chalmers JD, Hill AT, Karadag B, Midulla F, McCallum GB, Powell Z, Snijders D, Song WJ, Tonia T, Wilson C, Zacharasiewicz A, Kantar A. [European Respiratory Society guidelines for the management of children and adolescents with bronchiectasis.](#) *Eur Respir J*. 2021;58(2):2002990.
15. **Goyal V, Grimwood K**, Ware RS, Byrnes CA, Morris PS, Masters IB, McCallum GB, Binks MJ, Smith-Vaughan H, O'Grady KF, Champion A, Buntain HM, Schultz A, Chatfield M, Torzillo PJ, Chang AB. [Efficacy of oral amoxicillin-clavulanate or azithromycin for non-severe respiratory exacerbations in children with bronchiectasis \(BEST-1\): a multicentre, three-arm, double-blind, randomised placebo-controlled trial.](#) *Lancet Respir Med*. 2019;7(9):791-80.
16. Vicendese, D., Yerkovich, S., Grimwood, K., Valery, P. C., Byrnes, C. A., Morris, P. S., Dharmage, S. C. & Chang, A. B. 2023. Long-Term Azithromycin In Children With Bronchiectasis Unrelated To Cystic Fibrosis: Treatment Effects Over Time. *Chest*, 163, 52-63.

Guideline revision and approval history

Version No.	Modified by	Amendments authorised by	Approved by
1.0 20/12/2018 (supersedes CHQ-GDL- 01059)	Paediatric Respiratory Consultant Team (CHQ) Paediatric Infectious Diseases Consultant team (CHQ) Antimicrobial Stewardship Pharmacist (CHQ)	Divisional Director Medicine	Executive Director Clinical Services (QCH)
2.0 12/07/2019	Paediatric Respiratory Consultant and Fellow Team (CHQ) Paediatric Infectious Diseases Consultant and Fellow team (CHQ) Pharmacist Advanced - Antimicrobial Stewardship (CHQ)	CHQ Medicines Advisory Committee (QCH)	Executive Director Clinical Services (QCH)
2.1 30/06/2020	Director - Respiratory and Sleep Medicine (CHQ) Director – Infection Management and Prevention service (CHQ) Pharmacist Advanced - Antimicrobial Stewardship (CHQ)	Divisional Director Medicine	Executive Director Clinical Services (QCH)
3.0 23/07/2021	Director - Respiratory and Sleep Medicine (CHQ) Director – Infection Management and Prevention service (CHQ) Clinical Pharmacist Lead - Antimicrobial Stewardship (CHQ)	Divisional Director Medicine	Executive Director Clinical Services (QCH)
4.0 25/08/2023	Director – Infection Management and Prevention service (CHQ) SMOs- Respiratory and Sleep Medicine (CHQ) Pharmacist Advanced - Antimicrobial Stewardship (CHQ)	Divisional Director Medicine	Executive Director Clinical Services (QCH)

Keywords	Amoxicillin-Clavulanate, Azithromycin, Cefotaxime, Ceftazidime, Ceftriaxone, Ciprofloxacin, Colistin, Eradication, Exacerbation, Flucloxacillin, Inpatient Management, Non-CF bronchiectasis, Outpatient Management, Piperacillin/Tazobactam, Pseudomonas aeruginosa, Staphylococcus aureus, Methicillin resistant Staphylococcus aureus, Tobramycin, Trimethoprim/Sulfamethoxazole, 01072
Accreditation references	<p>National Safety and Quality Health Service Standards (1-8):</p> <ul style="list-style-type: none"> • Standard 3: Preventing and Controlling Healthcare-Associated Infection • Standard 4: Medication Safety